Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,600.00
Bid: 1,598.00
Ask: 1,598.50
Change: -4.50 (-0.28%)
Spread: 0.50 (0.031%)
Open: 1,613.00
High: 1,613.00
Low: 1,589.00
Prev. Close: 1,604.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Financials pace gains as Footsie keeps climbing

Mon, 20th Jun 2016 12:29

(ShareCast News) - Stocks in London were continuing to move higher come midday on Monday, alongside the largest gain the pound in three months, with investors taking their cue from strong gains in Asia as Brexit polls showed the Remain campaign was in the lead.As of 12:03 BST, the FTSE 100 was 183.60 points or 3.05% higher at 6,204.69, led higher by gains in financials such as Hargreaves Lansdown and RBS together with housebuilders, including Taylor Wimpey and Barratt Developments.Against the US dollar, the pound was gaining 1.84% to 1.4629. In parallel, front month Brent crude futures gained 1.64% to $49.99 per barrel on the ICE. Three-month LME-traded copper futures on the other hand were down by 1.2% to $4,552 per metric tonne.Over the weekend, a Survation poll in the Daily Mail revealed that support for the 'Remain' campaign was in the lead at 45.0% versus 42.0% for 'Leave', while two YouGov polls - one for ITV's Good Morning Britain and one for the Sunday Times - both showed Remain in front.In addition, a ComRes poll for the Sunday Mirror revealed the percentage of people saying they'd be relieved if the UK stayed in the EU rose to 45% after the murder of MP Jox Cox, from 35% before.Meanwhile, an opinion survey conducted for the Observer between Tuesday and Friday showed an even split but of the 10% undecided, 36% said they were leaning towards Remain.According to Oddschecker's tally of the odds being offered by bookmakers, the chances of 'Remain' coming out on top were being put at 31%, down from a record 44.0% just before the killing of lawmaker Jo Cox."We're still getting some rather ludicrous predictions of what the pound might do in the event of a "leave" vote, which to some extent has caused some rather extreme positioning, and will likely contribute to a lot more choppiness in the coming days, as this morning's Asia surge catches an awful lot of people the wrong way round," said Michael Hewson, chief market analyst at CMC Markets UK.BT Group, TalkTalk jump"With growing mobile data usage, we see mobile as an essential utility," UBS analyst Polo Tang said in a research note sent to clients. In case of 'Bremain', Tang expected a rebound in the likes of Sky, BT and TalkTalk. Those UK-centric three names had already underperformed going into the EU referendum (although they were relatively resilient operationally in the last downturn), he said.Heavily indebted North Sea oil producer EnQuest has denied media reports that it is in talks with the UK Oil and Gas Authority (OAG) about contingency plans. The government body fears insolvencies at Enquest and mid-cap peer Premier Oil, the Sunday Telegraph reported, and is mulling plans "to guard against a North Sea bankruptcy crisis" as the pair are "wracked with debt following the oil market rout and now stand at the mercy of their lenders".Gemfields, a British supplier of responsibly sourced coloured gemstones, reported record total revenues of $44.3m at a recent auction of rough rubies in Singapore as the increasing quality of Mozambique gems attracts growing demand.Shares in biopharmaceutical development company Circassia Pharmaceuticals plummeted on Monday morning, after it announced disappointing top-line results from its investigational cat allergy immunotherapy phase III study.Hammerson said it has exchanged contracts and completed the sale of Thurrock Shopping Park, Essex, to TH Real Estate for £93m. The sale price represents a net initial yield of 5.3% and is moderately below the book value as at 31 December 2015, Hammerson said.Late-stage drug trials by GlaxoSmithKline on its treatment for chronic obstructive pulmonary disease (COPD) have proved successful. The Phase III clinical testing by GSK and project partner Innoviva delivered data that is likely to support European regulatory submission by the end of 2016.FTSE 250 precision instruments maker Spectris has completed the acquisition of the software and associated assets of privately-held software solutions company Capstone Technology Corp for $22.5m. Capstone comprises two key software platforms: the MACS software suite providing engineering services and software for advanced process control optimisation and dataPARC, which is a data historian, visualisation and analytics software suite for operational decision support.Market MoversFTSE 100 (UKX) 6,216.27 3.24%FTSE 250 (MCX) 16,904.12 2.94%techMARK (TASX) 3,060.79 3.20%FTSE 100 - RisersHargreaves Lansdown (HL.) 1,320.00p 7.40%Royal Bank of Scotland Group (RBS) 238.40p 7.34%Taylor Wimpey (TW.) 187.80p 6.70%Worldpay Group (WI) (WPG) 291.70p 6.50%Barratt Developments (BDEV) 566.00p 6.49%Lloyds Banking Group (LLOY) 69.26p 6.47%St James's Place (STJ) 875.50p 6.25%Barclays (BARC) 175.95p 6.15%Aviva (AV.) 431.40p 6.02%International Consolidated Airlines Group SA (CDI) (IAG) 505.50p 5.69%FTSE 100 - FallersRandgold Resources Ltd. (RRS) 6,445.00p -2.50%Fresnillo (FRES) 1,213.00p -1.14%Rexam (REX) 627.50p -0.32%SABMiller (SAB) 4,288.00p 0.76%Rio Tinto (RIO) 2,028.00p 1.12%Antofagasta (ANTO) 431.30p 1.75%Hikma Pharmaceuticals (HIK) 2,189.00p 2.00%HSBC Holdings (HSBA) 440.25p 2.10%National Grid (NG.) 979.00p 2.11%BHP Billiton (BLT) 848.40p 2.12%FTSE 250 - RisersEvraz (EVR) 118.60p 8.71%Paragon Group Of Companies (PAG) 294.30p 6.82%Greggs (GRG) 1,089.00p 6.66%St. Modwen Properties (SMP) 318.40p 6.38%AA (AA.) 279.80p 6.27%Bovis Homes Group (BVS) 986.50p 6.25%Bellway (BWY) 2,711.00p 6.23%Serco Group (SRP) 109.60p 6.10%Unite Group (UTG) 640.50p 6.04%Virgin Money Holdings (UK) (VM.) 342.70p 6.03%FTSE 250 - FallersCircassia Pharmaceuticals (CIR) 96.75p -64.21%Centamin (DI) (CEY) 109.10p -1.89%Acacia Mining (ACA) 330.90p -1.63%Allied Minds (ALM) 330.00p -1.29%Templeton Emerging Markets Inv Trust (TEM) 459.40p -0.73%P2P Global Investments (P2P) 844.00p -0.65%BH Macro Ltd. GBP Shares (BHMG) 1,939.00p -0.41%Riverstone Energy Limited (RSE) 866.50p -0.40%Vectura Group (VEC) 156.60p -0.25%IP Group (IPO) 167.20p -0.18%
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.